<DOC>
	<DOCNO>NCT00767325</DOCNO>
	<brief_summary>The purpose study assess early sign response abatacept+methotrexate metacarpophalangeal joint hand use power Doppler ultrasonography patient active rheumatoid arthritis .</brief_summary>
	<brief_title>A Rheumatoid Arthritis Study Assess Early Response Abatacept+MTX Defined Improvement Synovitis Measures Power Doppler Ultrasonography</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Key inclusion riteria : Disease activity define disease activity score 28Creactive protein &gt; 3.2 , meet follow criterion : tender joint count ≥6 ; swell joint count ≥6 ; Creactive protein measurement great upper limit normal Diagnosis rheumatoid arthritis longer 6 month time initial diagnosis Total synovitis power Doppler ultrasonography ( PDUS ) score &gt; 1 least 2 metacarpophalangeal ( MCP ) joint ( MCP25 ) total synovitis PDUS score ≥1 least 1 MCP joint ( MCP25 ) Concomitant treatment methotrexate dose ≥15 mg least 3 month Day 1 stable dose last 28 day Day 1 No treatment background nonbiologic diseasemodifying antirheumatic drug ( DMARD ) methotrexate least 28 day treatment ( Day 1 ) Stable dose corticosteroid equivalent 10 mg prednisone /day 28 day prior Day 1 Naive treatment biologic DMARDs Key exclusion criterion : Women childbearing potential unwilling unable use birth control Women pregnant breastfeed Meeting diagnostic criterion rheumatic disease Previous MCP arthroplasty , procedure schedule , anticipate need procedure study . Participants undergone schedule undergo joint arthroplasty MCP joint permit enroll study provide eligibility criterion meet . Active vasculitis major organ system exception rheumatoid nodule Current symptom severe , progressive , uncontrolled renal , hepatic , hematologic , gastrointestinal , pulmonary , cardiac , neurologic , cerebral disease , whether related rheumatoid arthritis History cancer last 5 year , nonmelanoma skin cell cancer cure local resection carcinoma situ . Existing nonmelanoma skin cell cancer remove , lesion site heal , residual cancer rule prior administration study medication Clinically significant abuse alcohol drug Evidence active latent bacterial viral infection time potential enrollment Herpes zoster cytomegalovirus infection resolve less 2 month inform consent document sign For participant risk tuberculosis ( TB ) : A history active ( TB ) within last 3 year , even treat Latent TB successfully treat ≥4 week Current clinical , radiographic , laboratory evidence active TB . Participants receive live vaccine within 3 month anticipate first dose study medication Participants positive test result hepatitis B surface antigen hepatitis C antibody , hepatitis C virus detect polymerase chain reaction recombinant immunoblot assay . Participants hemoglobin level &lt; 8.5 g/dL white blood cell count &lt; 3000/mm^3 platelet count &lt; 100,000/mm^3 serum creatinin level &gt; 2*the upper limit normal ( ULN ) serum alanine transaminase level aspartate aminotransferase level &gt; 2*ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>